rebimastat

Small moleculeexperimental

Clinical trial activity

5 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2000 (NCT00006229)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
Mol. weight
499.68 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bms-275291
  • bms-275291
  • bms-275291
  • bms-275291
  • bms-275291-01
  • bms-275291-01
  • d2163
  • d2163
  • d-2163
  • n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide
  • rebimastat
  • rebimastat
  • rebimastat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00036621Phase 2May 11, 2002Bristol-Myers Squibb
NCT00040755Phase 2May 1, 2002National Cancer Institute (NCI), University of California, Davis
NCT00039104Phase 2Apr 1, 2002Mayo Clinic, National Cancer Institute (NCI)
NCT00024024Phase 1/Phase 2 (Phase 2)Aug 1, 2001National Cancer Institute (NCI), Northwestern University
NCT00006229Phase 2/Phase 3 (Phase 3)Apr 1, 2000Canadian Cancer Trials Group, University of Alberta
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3312001
Bristol-Myers SquibbFor profit1112002
Canadian Cancer Trials GroupAcademic/Hospital1112000
Mayo ClinicAcademic/Hospital1012002
Northwestern UniversityAcademic/Hospital1012001
University of AlbertaAcademic/Hospital1012000
University of California, DavisAcademic/Hospital1012002
7 organizations
Page 1 / 1